JPRN-jRCT2080222606未知1 期
Phase I, Multiple Oral Dose Study to Evaluate the Tolerability and Pharmacokinetics of Favipiravir in Healthy Volunteers
Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)0 个研究点目标入组 10 人开始时间: 2014年9月20日最近更新:
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 39age old（—）
- 性别
- Male
入选标准
- •Healthy adult volunteers
排除标准
- •Patients with a medical history which could influence on the evaluation of safety and pharmacokinetics
研究者
相似试验
尚未招募
不适用
A Phase I study to evaluate a single oral dose of SRT2379 on the endotoxin induced inflammatory response in healthy male subjectsDoor endotoxine veroorzaakte inflammatie reactieInflammationinnate immunesystem10002252NL-OMON36662Sirtris Pharmaceuticals, Inc.16
未知
1 期
A Phase 1 Study of ONO-2160/CDParkinson's diseaseJPRN-jRCT2080222651ONO PHARMACEUTICAL CO.,LTD.34
进行中（未招募）
1 期
A research project for boys with Duchenne muscular dystrophy aged 5-9 years. It aims to find out how safe and well tolerated different doses of the experimental medicine are, when given by mouth after breakfast and evening meal.Duchenne muscular dystrophy (DMD)MedDRA version: 18.1 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-001967-38-GBSummit (Oxford) Limited24
未知
1 期
A Phase 1 Study of ONO-2160/CDParkinson's diseaseJPRN-jRCT2080222143ONO PHARMACEUTICAL CO.,LTD.42
已完成
不适用
An open-label, multiple oral dose study to investigate the plasma and CSF pharmacokinetics of CAD-1883 in healthy volunteersNL-OMON47994Cadent Therapeutics Inc.8